Your session is about to expire
← Back to Search
Baricitinib for AGS
Study Summary
This trial is testing a new drug to see if it is safe and effective for people with Aicardi-Goutieres Syndrome, a rare disorder that affects many parts of the body.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2015 Phase 3 trial • 1307 Patients • NCT01710358Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Your lab test results are not within the normal range for your age and location, and it's not due to a known condition.I haven't taken immune-weakening drugs recently.I am a woman of childbearing age and not pregnant, using birth control.I weigh more than 4.5 kg.I have been diagnosed with Aicardi Goutières Syndrome.I have tested positive for TB or have a history of TB.I have symptoms like small head size, muscle weakness, stiff muscles, skin issues, liver inflammation, or blood problems.I am willing and able to follow the study's requirements.My genetic test shows a mutation linked to my condition.My brain scans show signs of disease, like calcifications or white matter disease.You have tested positive for hepatitis B.I have tested positive for Hepatitis C.I am older than 1 month.You have HIV infection or test positive for HIV antibodies.I am not taking any medication that is not allowed in the study.
- Group 1: Aicardi Goutières Syndrome patients receiving Baricitinib
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Have any other investigations been conducted around Baricitinib?
"Currently, Baricitinib is being tested in 31 distinct studies, 15 of which are entering the final phase. While several trials take place within Pune, Maharashtra, a total of 1416 medical centres have been enlisted to conduct research on this drug."
How many individuals are currently participating in this clinical experiment?
"This clinical trial is no longer open for recruitment. It was initially announced on June 3rd 2019 and the last update occurred on July 19th 2022. If you are looking to participate in other studies, there are 1389 trials actively enrolling patients with Aicardi-Goutieres Syndrome and 31 studies involving Baricitinib recruiting participants."
To what end is Baricitinib usually prescribed?
"Commonly administered to hospitalized individuals, baricitinib can also be utilized for the management of conditions such as coronavirus disease 2019 (covid‑19), extracorporeal membrane oxygenation treatment, and rheumatoid arthritis."
What deleterious effects can Baricitinib have on patients?
"Baricitinib has only been tested for safety in a Phase 2 trial, so it is assigned an estimated risk level of 2. There have yet to be any reported studies validating its efficacy."
Are enrollment slots currently available for this research study?
"Per the clinicaltrials.gov database, this trial is not actively searching for enrollees at present. Originally posted on June 3rd 2019 with a last update of July 19th 2022, it currently has no recruitment requirements; however, there are over 1400 other trials looking to take in participants as we speak."
Share this study with friends
Copy Link
Messenger